Search hospitals > Minnesota > Minneapolis
University of Minnesota/Masonic Cancer Center
Claim this profileMinneapolis, Minnesota 55455
Global Leader in Cancer
Global Leader in Adult T-Cell Leukemia/Lymphoma
Conducts research for Lymphoma
Conducts research for Leukemia
Conducts research for Solid Tumors
723 reported clinical trials
35 medical researchers
Summary
University of Minnesota/Masonic Cancer Center is a medical facility located in Minneapolis, Minnesota. This center is recognized for care of Cancer, Adult T-Cell Leukemia/Lymphoma, Lymphoma, Leukemia, Solid Tumors and other specialties. University of Minnesota/Masonic Cancer Center is involved with conducting 723 clinical trials across 729 conditions. There are 35 research doctors associated with this hospital, such as Emily Greengard, Manish Patel, Christopher Moertel, and Peter M. Gordon.Area of expertise
1Cancer
Global LeaderStage IV
Stage I
Stage II
2Adult T-Cell Leukemia/Lymphoma
Global LeaderStage II
Stage I
Stage III
Top PIs
Emily GreengardUniversity of Minnesota/Masonic Cancer Center5 years of reported clinical research
Expert in Cancer
Expert in Neuroblastoma
46 reported clinical trials
74 drugs studied
Manish PatelFlorida Cancer Specialists4 years of reported clinical research
Expert in Solid Tumors
Expert in Cancer
31 reported clinical trials
49 drugs studied
Christopher MoertelUniversity of Minnesota/Masonic Cancer Center5 years of reported clinical research
Studies Neurofibromatosis
Studies Brain Tumor
15 reported clinical trials
24 drugs studied
Peter M. GordonUniversity of Minnesota/Masonic Cancer Center5 years of reported clinical research
Studies Adult T-Cell Leukemia/Lymphoma
Studies Acute Lymphoblastic Leukemia
13 reported clinical trials
39 drugs studied
Clinical Trials running at University of Minnesota/Masonic Cancer Center
Breast Cancer
Cancer
Lymphoma
Myelodysplastic Syndrome
Acute Lymphoblastic Leukemia
Adult T-Cell Leukemia/Lymphoma
Brain Tumor
Leukemia
Non-Hodgkin's Lymphoma
Acute Myeloid Leukemia
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
[225Ac]-FPI-1434
for Cancer
This is a first-in-human Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, PK, and preliminary anti-tumour activity of \[225Ac\]-FPI-1434 (radioimmuno-therapeutic agent) in patients with solid tumours that demonstrate uptake of \[111In\]-FPI-1547 (radioimmuno-imaging agent), and to establish the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of repeat doses of \[225Ac\]-FPI-1434 Injection in patients with solid tumours that demonstrate uptake of \[111In\]-FPI-1547 (radioimmuno-imaging agent).
Recruiting1 award Phase 1 & 211 criteria
Alisertib + Endocrine Therapy
for Breast Cancer
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two prior lines of endocrine therapy in the recurrent or metastatic setting. This study is intended to evaluate the optimal alisertib dose administered in combination with the selected endocrine therapy. The study is also planned to evaluate the efficacy, safety, and pharmacokinetics of alisertib in combination with endocrine and to identify the biomarker-defined subgroup(s) that may benefit most from combined alisertib and endocrine therapy.
Recruiting1 award Phase 2
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at University of Minnesota/Masonic Cancer Center?
Where is University of Minnesota/Masonic Cancer Center located?
Who should I call to ask about financial aid or insurance network?
What insurance does University of Minnesota/Masonic Cancer Center accept?
What awards or recognition has University of Minnesota/Masonic Cancer Center received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.